The necessity of neostrimin to counteract residual muscle relaxations in patients under general anesthesia during recovery

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066433

Enrollment

Unknown

Registered

2022-12-05

Start date

2022-12-10

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications after general anesthesia

Interventions

Muscle relaxation antagonist group:Neostigmine

Blank control group:Normal saline solution

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Day surgery ward patients aged 18-60 with non-thoracic and abdominal surgery; ASA grade I-II; 18.5kg/m2<BMI<24.0kg/m^2; Preoperative cardiopulmonary function was normal, no history of thoracic and abdominal operations; There are no clear factors affecting TOF monitoring, such as neuromuscular disease, or the use of related drugs that affect neuromuscular function.

Exclusion criteria

Exclusion criteria: Poor compliance during entry and induction; BMI30kg/m^2; Previous abnormal cardiopulmonary function, or a history of thoracic and abdominal surgery; Have a history of neurological disorders or have taken or are taking medications that affect neuromuscular function.

Design outcomes

Primary

Measure	Time frame
Degree of diaphragm movement;Rate of change of diaphragm thickness;	—

Countries

China

Contacts

Public ContactYunan Lin

The First Affiliated Hospital of Guangxi Medical University

277464077@qq.com+86 13768278751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026